Route of administration other than oral for concomitant me­di­cation [Bioanalytics]

posted by Ohlbe – France, 2020-02-05 11:13 (1482 d 07:00 ago) – Posting: # 21147
Views: 2,159

Dear Qualityassurance,

❝ Can anyone suggest me :confused::confused: if it is required to include these medications in concomitant medication experiment if the route of administration is other than oral (e.g. IV, topical, eye drops) during clinical phase?


I would say it depends on the bioavailability of these products when administered by these routes. For IV, no discussion (at least, if there is an active substance - don't bother about saline or glucose). But for a topical administration the answer is likely that there is no point.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
22,912 posts in 4,806 threads, 1,635 registered users;
32 visitors (0 registered, 32 guests [including 7 identified bots]).
Forum time: 18:14 CET (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5